ENDOSC-CLAD: Endobronchial allogeneic mesenchymal stromal cells for lung transplant chronic rejection

Phase 2, randomised, open-label trial of human mesenchymal stromal cells in Bronchiolitis Obliterans Syndrome (BOS) and chronic lung allograft dysfunction (CLAD) (2 arms), sponsored by Fundación de Investigación Biomédica Hospital Puerta de Hierro. Primary endpoint: Incidence of early-onset adverse events within 24 hours after MSC administration. Started Mar 2022; status: active.